In a trial involving 13,000 adults, the vaccine demonstrated an efficacy rate of 64.7% against symptomatic COVID, and 72% efficacy against infections specifically caused by the Omicron variant.
from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/Yxbg6SB
Home »
Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com
» Sanofi, GSK variant-specific COVID shot found effective against Omicron
https://ift.tt/70sUDyz
No comments:
Post a Comment